Respiratory muscle overloading and dyspnoea during bronchoconstriction in asthma: Protective effects of fenoterol

Gianni Misuri, Marco Mancini, Iacopo Iandelli, Roberto Duranti, Loredana Stendardi, Francesco Gigliotti, Elisabetta Rosi, Maria Cristina Ronchi, Giorgio Scano

Research output: Contribution to journalArticle

Abstract

Whether, and to what extent, β2-agonists protect against respiratory muscle overloading and breathlessness during bronchoconstriction remains to be defined in patients with asthma. In a double blind placebo-controlled study, 100 μg of fenoterol were administered to six stable asthmatics before a bronchial provocation test, performed by inhaling doubling concentrations of histamine from a Devilbiss 646 nebulizer. We recorded breathing pattern (tidal volume V(T), inspiratory time T(I), total time of the respiratory cycle T(TOT)), inspiratory capacity (IC), dynamic pleural pressure swing (P(plsw)), total lung resistance (R(L)) and FEV1. V(T) was expressed both in actual values and as % of IC. Changes in V(T) (%IC) during histamine inhalation reflected changes in dynamic end-inspiratory lung volume (EILV). P(plsw) was expressed as % of maximal (the most negative in sign) pleural pressure, obtained under control conditions during a sniff manoeuvre (P(plsn)). P(plsw)(%P(plsn)) is an index of inspiratory muscle effort. The test ended when the concentration of histamine which caused a decrease in FEV1 of ≥ 40% post-saline was reached. Dyspnoea rating was scored by a modified Borg scale. At the ultimate degree of bronchoconstriction (UDB) with histamine: (i) decrease in FEV1 was similar after placebo and fenoterol, while increase in R(L) was lower after fenoterol (P <0.005); (ii) V(T)(%IC) increased less after fenoterol (P <0.027); (iii) increases in P(plsw)(%P(plsw)) was lower after fenoterol (P <0.001); (iv) ΔBorg (from saline) was lower (P <0.01) after fenoterol; (v) differences in ΔBorg, from placebo to fenoterol, related to concurrent changes in V(T)(%IC) (r2 = 0.67). In conclusion, at UDB 100 μg of fenoterol produced a beneficial effect on the degree of inspiratory muscle loading and breathlessness, an effect greater than it would be expected from measuring FEV1 alone.

Original languageEnglish
Pages (from-to)299-304
Number of pages6
JournalPulmonary Pharmacology and Therapeutics
Volume10
Issue number5-6
DOIs
Publication statusPublished - Oct 1997

Fingerprint

Fenoterol
Respiratory Muscles
Bronchoconstriction
Dyspnea
Inspiratory Capacity
Muscle
Asthma
Histamine
Placebos
Inhalation
Bronchial Provocation Tests
Pressure
Muscles
Lung
Nebulizers and Vaporizers
Tidal Volume
Respiration

Keywords

  • Asthma
  • Dyspnoea
  • Fenoterol
  • Respiratory muscles

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

Respiratory muscle overloading and dyspnoea during bronchoconstriction in asthma : Protective effects of fenoterol. / Misuri, Gianni; Mancini, Marco; Iandelli, Iacopo; Duranti, Roberto; Stendardi, Loredana; Gigliotti, Francesco; Rosi, Elisabetta; Ronchi, Maria Cristina; Scano, Giorgio.

In: Pulmonary Pharmacology and Therapeutics, Vol. 10, No. 5-6, 10.1997, p. 299-304.

Research output: Contribution to journalArticle

Misuri, G, Mancini, M, Iandelli, I, Duranti, R, Stendardi, L, Gigliotti, F, Rosi, E, Ronchi, MC & Scano, G 1997, 'Respiratory muscle overloading and dyspnoea during bronchoconstriction in asthma: Protective effects of fenoterol', Pulmonary Pharmacology and Therapeutics, vol. 10, no. 5-6, pp. 299-304. https://doi.org/10.1006/pupt.1998.0108
Misuri, Gianni ; Mancini, Marco ; Iandelli, Iacopo ; Duranti, Roberto ; Stendardi, Loredana ; Gigliotti, Francesco ; Rosi, Elisabetta ; Ronchi, Maria Cristina ; Scano, Giorgio. / Respiratory muscle overloading and dyspnoea during bronchoconstriction in asthma : Protective effects of fenoterol. In: Pulmonary Pharmacology and Therapeutics. 1997 ; Vol. 10, No. 5-6. pp. 299-304.
@article{d6730e2e7af7495b8e832a27c60e810f,
title = "Respiratory muscle overloading and dyspnoea during bronchoconstriction in asthma: Protective effects of fenoterol",
abstract = "Whether, and to what extent, β2-agonists protect against respiratory muscle overloading and breathlessness during bronchoconstriction remains to be defined in patients with asthma. In a double blind placebo-controlled study, 100 μg of fenoterol were administered to six stable asthmatics before a bronchial provocation test, performed by inhaling doubling concentrations of histamine from a Devilbiss 646 nebulizer. We recorded breathing pattern (tidal volume V(T), inspiratory time T(I), total time of the respiratory cycle T(TOT)), inspiratory capacity (IC), dynamic pleural pressure swing (P(plsw)), total lung resistance (R(L)) and FEV1. V(T) was expressed both in actual values and as {\%} of IC. Changes in V(T) ({\%}IC) during histamine inhalation reflected changes in dynamic end-inspiratory lung volume (EILV). P(plsw) was expressed as {\%} of maximal (the most negative in sign) pleural pressure, obtained under control conditions during a sniff manoeuvre (P(plsn)). P(plsw)({\%}P(plsn)) is an index of inspiratory muscle effort. The test ended when the concentration of histamine which caused a decrease in FEV1 of ≥ 40{\%} post-saline was reached. Dyspnoea rating was scored by a modified Borg scale. At the ultimate degree of bronchoconstriction (UDB) with histamine: (i) decrease in FEV1 was similar after placebo and fenoterol, while increase in R(L) was lower after fenoterol (P <0.005); (ii) V(T)({\%}IC) increased less after fenoterol (P <0.027); (iii) increases in P(plsw)({\%}P(plsw)) was lower after fenoterol (P <0.001); (iv) ΔBorg (from saline) was lower (P <0.01) after fenoterol; (v) differences in ΔBorg, from placebo to fenoterol, related to concurrent changes in V(T)({\%}IC) (r2 = 0.67). In conclusion, at UDB 100 μg of fenoterol produced a beneficial effect on the degree of inspiratory muscle loading and breathlessness, an effect greater than it would be expected from measuring FEV1 alone.",
keywords = "Asthma, Dyspnoea, Fenoterol, Respiratory muscles",
author = "Gianni Misuri and Marco Mancini and Iacopo Iandelli and Roberto Duranti and Loredana Stendardi and Francesco Gigliotti and Elisabetta Rosi and Ronchi, {Maria Cristina} and Giorgio Scano",
year = "1997",
month = "10",
doi = "10.1006/pupt.1998.0108",
language = "English",
volume = "10",
pages = "299--304",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press",
number = "5-6",

}

TY - JOUR

T1 - Respiratory muscle overloading and dyspnoea during bronchoconstriction in asthma

T2 - Protective effects of fenoterol

AU - Misuri, Gianni

AU - Mancini, Marco

AU - Iandelli, Iacopo

AU - Duranti, Roberto

AU - Stendardi, Loredana

AU - Gigliotti, Francesco

AU - Rosi, Elisabetta

AU - Ronchi, Maria Cristina

AU - Scano, Giorgio

PY - 1997/10

Y1 - 1997/10

N2 - Whether, and to what extent, β2-agonists protect against respiratory muscle overloading and breathlessness during bronchoconstriction remains to be defined in patients with asthma. In a double blind placebo-controlled study, 100 μg of fenoterol were administered to six stable asthmatics before a bronchial provocation test, performed by inhaling doubling concentrations of histamine from a Devilbiss 646 nebulizer. We recorded breathing pattern (tidal volume V(T), inspiratory time T(I), total time of the respiratory cycle T(TOT)), inspiratory capacity (IC), dynamic pleural pressure swing (P(plsw)), total lung resistance (R(L)) and FEV1. V(T) was expressed both in actual values and as % of IC. Changes in V(T) (%IC) during histamine inhalation reflected changes in dynamic end-inspiratory lung volume (EILV). P(plsw) was expressed as % of maximal (the most negative in sign) pleural pressure, obtained under control conditions during a sniff manoeuvre (P(plsn)). P(plsw)(%P(plsn)) is an index of inspiratory muscle effort. The test ended when the concentration of histamine which caused a decrease in FEV1 of ≥ 40% post-saline was reached. Dyspnoea rating was scored by a modified Borg scale. At the ultimate degree of bronchoconstriction (UDB) with histamine: (i) decrease in FEV1 was similar after placebo and fenoterol, while increase in R(L) was lower after fenoterol (P <0.005); (ii) V(T)(%IC) increased less after fenoterol (P <0.027); (iii) increases in P(plsw)(%P(plsw)) was lower after fenoterol (P <0.001); (iv) ΔBorg (from saline) was lower (P <0.01) after fenoterol; (v) differences in ΔBorg, from placebo to fenoterol, related to concurrent changes in V(T)(%IC) (r2 = 0.67). In conclusion, at UDB 100 μg of fenoterol produced a beneficial effect on the degree of inspiratory muscle loading and breathlessness, an effect greater than it would be expected from measuring FEV1 alone.

AB - Whether, and to what extent, β2-agonists protect against respiratory muscle overloading and breathlessness during bronchoconstriction remains to be defined in patients with asthma. In a double blind placebo-controlled study, 100 μg of fenoterol were administered to six stable asthmatics before a bronchial provocation test, performed by inhaling doubling concentrations of histamine from a Devilbiss 646 nebulizer. We recorded breathing pattern (tidal volume V(T), inspiratory time T(I), total time of the respiratory cycle T(TOT)), inspiratory capacity (IC), dynamic pleural pressure swing (P(plsw)), total lung resistance (R(L)) and FEV1. V(T) was expressed both in actual values and as % of IC. Changes in V(T) (%IC) during histamine inhalation reflected changes in dynamic end-inspiratory lung volume (EILV). P(plsw) was expressed as % of maximal (the most negative in sign) pleural pressure, obtained under control conditions during a sniff manoeuvre (P(plsn)). P(plsw)(%P(plsn)) is an index of inspiratory muscle effort. The test ended when the concentration of histamine which caused a decrease in FEV1 of ≥ 40% post-saline was reached. Dyspnoea rating was scored by a modified Borg scale. At the ultimate degree of bronchoconstriction (UDB) with histamine: (i) decrease in FEV1 was similar after placebo and fenoterol, while increase in R(L) was lower after fenoterol (P <0.005); (ii) V(T)(%IC) increased less after fenoterol (P <0.027); (iii) increases in P(plsw)(%P(plsw)) was lower after fenoterol (P <0.001); (iv) ΔBorg (from saline) was lower (P <0.01) after fenoterol; (v) differences in ΔBorg, from placebo to fenoterol, related to concurrent changes in V(T)(%IC) (r2 = 0.67). In conclusion, at UDB 100 μg of fenoterol produced a beneficial effect on the degree of inspiratory muscle loading and breathlessness, an effect greater than it would be expected from measuring FEV1 alone.

KW - Asthma

KW - Dyspnoea

KW - Fenoterol

KW - Respiratory muscles

UR - http://www.scopus.com/inward/record.url?scp=0031260623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031260623&partnerID=8YFLogxK

U2 - 10.1006/pupt.1998.0108

DO - 10.1006/pupt.1998.0108

M3 - Article

C2 - 9778494

AN - SCOPUS:0031260623

VL - 10

SP - 299

EP - 304

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 5-6

ER -